Interleukin-17 pathophysiology and therapeutic intervention in cystic fibrosis lung infection and inflammation

Infection and Immunity

Volumn 84, Issue 9, 2016, Pages 2410-2421

  Hsu, Daniel ^a   Taylor, Patricia ^b   Fletcher, Dave ^c   Van Heeckeren, Rolf ^c   Eastman, Jean ^b   Van Heeckeren, Anna ^c   Davis, Pamela ^c   Chmiel, James F ^c   Pearlman, Eric ^b,d   Bonfield, Tracey L ^c  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL3 CHEMOKINE; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 17; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CHEMOKINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

AIRWAY EPITHELIAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LUNG FIBROSIS; LUNG INFECTION; LYMPHOCYTE COUNT; MACROPHAGE; MOUSE; MURINE MODEL; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECTS; EPITHELIUM; LUNG; LUNG DISEASES; METABOLISM; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

ANIMALS; CELL LINE; CHEMOKINES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIUM; INTERLEUKIN-17; LUNG; LUNG DISEASES; MICE; MICE, INBRED C57BL; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84984832818     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00284-16     Document Type: Article

References (54)

1. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW. 2014. GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 190: 175-184. http://dx.doi.org/10.1164/rccm.201404-0703OC.
2. Nichols D, Chmiel J, Berger M. 2008. Chronic inflammation in the cystic fibrosis lung: alterations in inter-and intracellular signaling. Clin Rev Allergy Immunol 34: 146-162. http://dx.doi.org/10.1007/s12016-007-8039-9.
3. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. 2007. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 175: 822-828. http://dx.doi.org/10.1164/rccm.200609-1354OC.
4. Konstan MW, Doring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton A. 2014. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 13: 148-155. http://dx.doi.org/10.1016/j.jcf.2013.12.009.
5. + memory cells in lung draining lymph nodes. J Allergy Clin Immunol 131: 1117-1129. http://dx.doi.org/10.1016/j.jaci.2012.05.036.
6. Dubin PJ, Kolls JK. 2007. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 292: L519-L528. http://dx.doi.org/10.1152/ajplung.00312.2006.
7. Dubin PJ, McAllister F, Kolls JK. 2007. Is cystic fibrosis a TH17 disease?. Inflamm Res 56: 221-227. http://dx.doi.org/10.1007/s00011-007-6187-2.
8. Ling Y, Puel A. 2014. IL-17 and infections. Acta Dermosifiliogr 105(Suppl 1): S34-S40. http://dx.doi.org/10.1016/S0001-7310(14)70016-X.
9. Nembrini C, Marsland BJ, Kopf M. 2009. IL-17-producing T cells in lung immunity and inflammation. J Allergy Clin Immunol 123: 986-994. http://dx.doi.org/10.1016/j.jaci.2009.03.033.
10. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, Schwarzenberger P, Shellito JE, Kolls JK. 2001. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 25: 335-340. http://dx.doi.org/10.1165/ajrcmb.25.3.4424.
11. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito JE, Bagby GJ, Nelson S, Charrier K, Peschon JJ, Kolls JK. 2001. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194: 519-527. http://dx.doi.org/10.1084/jem.194.4.519.
12. McAleer JP, Kolls JK. 2014. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev 260: 129-144. http://dx.doi.org/10.1111/imr.12183.
13. Liu B, Tan W, Barsoum A, Gu X, Chen K, Huang W, Ramsay A, Kolls JK, Schwarzenberger P. 2010. IL-17 is a potent synergistic factor with GM-CSF in mice in stimulating myelopoiesis, dendritic cell expansion, proliferation, and functional enhancement. Exp Hematol 38: 877-884. http://dx.doi.org/10.1016/j.exphem.2010.06.004.
14. Decraene A, Willems-Widyastuti A, Kasran A, De Boeck K, Bullens DM, Dupont LJ. 2010. Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable cystic fibrosis patients. Respir Res 11: 177. http://dx.doi.org/10.1186/1465-9921-11-177.
15. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB. 2003. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 170: 2655-2662. http://dx.doi.org/10.4049/jimmunol.170.5.2655.
16. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA, van den Berg WB. 2001. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 167: 1004-1013. http://dx.doi.org/10.4049/jimmunol.167.2.1004.
17. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. 2006. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 12: 382-388. http://dx.doi.org/10.1097/01.MIB.0000218764.06959.91.
18. Afzal N, Zaman S, Asghar A, Javed K, Shahzad F, Zafar A, Nagi AH. 2014. Negative association of serum IL-6 and IL-17 with type-II diabetes retinopathy. Iran J Immunol 11: 40-48.
19. + CTL in the pathogenesis of type 1 diabetes and experimental autoimmune encephalomyelitis. J Clin Immunol 31: 811-826. http://dx.doi.org/10.1007/s10875-011-9549-z.
20. McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, Jaffee EM, Drake CG, Housseau F, Maitra A, Kolls JK, Sears CL, Pardoll DM, Leach SD. 2014. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25: 621-637. http://dx.doi.org/10.1016/j.ccr.2014.03.014.
21. Allen JE, Sutherland TE, Ruckerl D. 2015. IL-17 and neutrophils: unexpected players in the type 2 immune response. Curr Opin Immunol 34: 99-106. http://dx.doi.org/10.1016/j.coi.2015.03.001.
22. Ivanov S, Bozinovski S, Bossios A, Valadi H, Vlahos R, Malmhall C, Sjostrand M, Kolls JK, Anderson GP, Linden A. 2007. Functional relevance of the IL-23-IL-17 axis in lungs in vivo. Am J Respir Cell Mol Biol 36: 442-451. http://dx.doi.org/10.1165/rcmb.2006-0020OC.
23. Newcomb DC, Boswell MG, Huckabee MM, Goleniewska K, Dulek DE, Reiss S, Lukacs NW, Kolls JK, Peebles RS, Jr. 2012. IL-13 regulates Th17 secretion of IL-17A in an IL-10-dependent manner. J Immunol 188: 1027-1035. http://dx.doi.org/10.4049/jimmunol.1102216.
24. Tan HL, Rosenthal M. 2013. IL-17 in lung disease: friend or foe?. Thorax 68: 788-790. http://dx.doi.org/10.1136/thoraxjnl-2013-203307.
25. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, Magorien JE, Blauvelt A, Kolls JK, Cheung AL, Cheng G, Modlin RL, Miller LS. 2010. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 120: 1762-1773. http://dx.doi.org/10.1172/JCI40891.
26. Hazlett LD. 2005. Inflammatory response to Pseudomonas aeruginosa keratitis. Ocul Surf 3: S139-S141.
27. Li C, McClellan SA, Barrett R, Hazlett LD. 2014. Interleukin 17 regulates Mer tyrosine kinase-positive cells in Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 55: 6886-6900. http://dx.doi.org/10.1167/iovs.14-14522.
28. Liu J, Qu H, Li Q, Ye L, Ma G, Wan H. 2013. The responses of gammadelta T-cells against acute Pseudomonas aeruginosa pulmonary infection in mice via interleukin-17. Pathog Dis 68: 44-51. http://dx.doi.org/10.1111/2049-632X.12043.
29. Liu J, Feng Y, Yang K, Li Q, Ye L, Han L, Wan H. 2011. Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice. FEMS Immunol Med Microbiol 61: 179-188. http://dx.doi.org/10.1111/j.1574-695X.2010.00764.x.
30. Xu X, Shao B, Wang R, Zhou S, Tang Z, Lu W, Xiong S. 2014. Role of interleukin-17 in defense against Pseudomonas aeruginosa infection in lungs. Int J Clin Exp Med 7: 809-816.
31. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. 2011. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 184: 252-258. http://dx.doi.org/10.1164/rccm.201102-0236OC.
32. Taylor PR, Bonfield TL, Chmiel JF, Pearlman E. 4 May 2016. Neutrophils from F508del cystic fibrosis patients produce IL-17A and express IL-23-dependent IL-17C. Clin Immunol http://dx.doi.org/10.1016/j.clim.2016.03.016.
33. van Heeckeren AM, Schluchter MD. 2002. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim 36: 291-312. http://dx.doi.org/10.1258/002367702320162405.
34. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T. 1997. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 100: 2810-2815. http://dx.doi.org/10.1172/JCI119828.
35. van Heeckeren AM, Schluchter MD, Xue W, Davis PB. 2006. Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice. Am J Respir Crit Care Med 173: 288-296. http://dx.doi.org/10.1164/rccm.200506-917OC.
36. Bonfield TL, Hodges CA, Cotton CU, Drumm ML. 2012. Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection. J Leukoc Biol 92: 1111-1122. http://dx.doi.org/10.1189/jlb.0412188.
37. van Heeckeren AM, Tscheikuna J, Walenga RW, Konstan MW, Davis PB, Erokwu B, Haxhiu MA, Ferkol TW. 2000. Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. Am J Respir Crit Care Med 161: 271-279. http://dx.doi.org/10.1164/ajrccm.161.1.9903019.
38. van Heeckeren AM, Schluchter MD, Drumm ML, Davis PB. 2004. Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 287: L944-L952. http://dx.doi.org/10.1152/ajplung.00387.2003.
39. Saadane A, Eastman J, Berger M, Bonfield TL. 2011. Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells. J Inflamm (Lond) 8: 26. http://dx.doi.org/10.1186/1476-9255-8-26.
40. Saadane A, Soltys J, Berger M. 2006. Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation. J Allergy Clin Immunol 117: 1163-1169. http://dx.doi.org/10.1016/j.jaci.2006.01.052.
41. Happel KI, Zheng M, Young E, Quinton LJ, Lockhart E, Ramsay AJ, Shellito JE, Schurr JR, Bagby GJ, Nelson S, Kolls JK. 2003. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 170: 4432-4436. http://dx.doi.org/10.4049/jimmunol.170.9.4432.
42. Shih VF, Cox J, Kljavin NM, Dengler HS, Reichelt M, Kumar P, Rangell L, Kolls JK, Diehl L, Ouyang W, Ghilardi N. 2014. Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota. Proc Natl Acad Sci U S A 111: 13942-13947. http://dx.doi.org/10.1073/pnas.1323852111.
43. Dubin PJ, Kolls JK. 2011. IL-17 in cystic fibrosis: more than just Th17 cells. Am J Respir Crit Care Med 184: 155-157. http://dx.doi.org/10.1164/rccm.201104-0617ED.
44. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, McAllister F, Edeal J, Gaus K, Husain S, Kreindler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura Y, Kolls JK. 2008. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14: 275-281. http://dx.doi.org/10.1038/nm1710.
45. Chen Y, Qian T, Zhang D, Yan H, Hao F. 2015. Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis. Immunotherapy 7: 1023-1037. http://dx.doi.org/10.2217/imt.15.50.
46. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. 2005. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175: 6177-6189. http://dx.doi.org/10.4049/jimmunol.175.9.6177.
47. Newcomb DC, Boswell MG, Reiss S, Zhou W, Goleniewska K, Toki S, Harintho MT, Lukacs NW, Kolls JK, Peebles RS, Jr. 2013. IL-17A inhibits airway reactivity induced by respiratory syncytial virus infection during allergic airway inflammation. Thorax 68: 717-723. http://dx.doi.org/10.1136/thoraxjnl-2012-202404.
48. Pickens SR, Volin MV, Mandelin AM, Kolls JK, Pope RM, Shahrara S. 2010. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 184: 3233-3241. http://dx.doi.org/10.4049/jimmunol.0903271.
49. Kolls JK, Linden A. 2004. Interleukin-17 family members and inflammation. Immunity 21: 467-476. http://dx.doi.org/10.1016/j.immuni.2004.08.018.
50. Kolls JK. 2010. Th17 cells in mucosal immunity and tissue inflammation. Semin Immunopathol 32: 1-2. http://dx.doi.org/10.1007/s00281-010-0198-8.
51. Fang P, Zhou L, Zhou Y, Kolls JK, Zheng T, Zhu Z. 2014. Immune modulatory effects of IL-22 on allergen-induced pulmonary inflammation. PLoS One 9: e107454. http://dx.doi.org/10.1371/journal.pone.0107454.
52. Netea MG, van der Meer JW, Sutmuller RP, Adema GJ, Kullberg BJ. 2005. From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Chemother 49: 3991-3996. http://dx.doi.org/10.1128/AAC.49.10.3991-3996.2005.
53. Miossec P, Kolls JK. 2012. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11: 763-776. http://dx.doi.org/10.1038/nrd3794.
54. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, Pirhonen J, Kolls JK. 2005. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growthrelated oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 175: 404-412. http://dx.doi.org/10.4049/jimmunol.175.1.404.